These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 17216565

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. IL-15R alpha-chain expression during anti-CD25 treatment of cardiac allograft recipients.
    Baan CC, Balk AH, van der Plas AJ, van Gelder T, Vantrimpont PJ, Maat LP, Weimar W.
    Transplant Proc; 2002 Dec; 34(8):3243-5. PubMed ID: 12493434
    [No Abstract] [Full Text] [Related]

  • 23. Window of opportunity for daclizumab.
    Schluns KS.
    Nat Med; 2011 May; 17(5):545-7. PubMed ID: 21546970
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
    Sloand EM, Scheinberg P, Maciejewski J, Young NS.
    Ann Intern Med; 2006 Feb 07; 144(3):181-5. PubMed ID: 16461962
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
    Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.
    Proc Natl Acad Sci U S A; 2006 Apr 11; 103(15):5941-6. PubMed ID: 16585503
    [Abstract] [Full Text] [Related]

  • 29. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
    Li J, Li X, Tan M, Lin B, Hou S, Qian W, Li B, Zhang D, Zhou B, Wang H, Zhu T, Guo Y.
    MAbs; 2009 Apr 11; 1(1):49-55. PubMed ID: 20046574
    [Abstract] [Full Text] [Related]

  • 30. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
    Goebel J, Stevens E, Forrest K, Roszman TL.
    Transpl Immunol; 2000 Nov 11; 8(3):153-9. PubMed ID: 11147695
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
    Madsen M, Svendsen UG.
    Ugeskr Laeger; 2000 Oct 16; 162(42):5648-52. PubMed ID: 11059309
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
    Binder M, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M.
    Cancer Res; 2007 Apr 15; 67(8):3518-23. PubMed ID: 17440057
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
    Zhang Z, Zhang M, Garmestani K, Talanov VS, Plascjak PS, Beck B, Goldman C, Brechbiel MW, Waldmann TA.
    Blood; 2006 Aug 01; 108(3):1007-12. PubMed ID: 16569769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.